Impurities related to Brivaracetam

Brivaracetam is an anticonvulsant used for the treatment of partial-onset seizures that functions by binding to synaptic vesicle glycoprotein 2A (SV2A) in the brain.

Brivaracetam is a racetam derivative of levetiracetam. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam. It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016.

SZEB manufactures and supplies Brivaracetam impurities of certified standard. SZEB has more than 5000 impurities in stock. More information is available on the official website: https://www.ex-biotech.com/. If you have any questions, please send an email to ramyan@ex-biotech.com, we look forward to cooperating with you.